Skip to main content
    Q

    Q32 Bio Inc (QTTB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.29
    -0.42 (-4.82%)

    Market Cap: $260.64M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Q32 Bio Inc (QTTB) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Q32 Bio are SAB Biotherapeutics (SABS), ProQR Therapeutics BV (PRQR) and Tevogen Bio Holdings (TVGN). By market cap, Q32 Bio ranks 8th of the 13 companies on this page; Avalo Therapeutics (AVTX) is the largest at $448.71M.

    Peer Comparison

    QTTB's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Q32 Bio (QTTB)$260.64M2.5x5.2x60.0%N/A0.0%0.00%
    SAB Biotherapeutics Inc (SABS)$266.66MN/AN/A0.0%N/A-62.4%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    Nautilus Biotechnology Inc (NAUT)$295.50MN/A630.2x0.0%N/A0.0%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Kyverna Therapeutics, Inc. Common Stock (KYTX)$319.27MN/AN/A0.0%-81.5%0.0%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Entrada Therapeutics Inc (TRDA)$199.28MN/A53.3x0.0%-69.7%-43.9%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Century Therapeutics Inc (IPSC)$299.63MN/AN/A0.0%N/A-100.0%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Peer median$277.71M12.1x6.1x0.0%-54.0%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Q32 Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    SAB Biotherapeutics Inc (SABS)
    SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology.
    SABS competitors
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors
    Nautilus Biotechnology Inc (NAUT)
    Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome...
    NAUT competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Kyverna Therapeutics, Inc. Common Stock (KYTX)
    Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health...
    KYTX competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Entrada Therapeutics Inc (TRDA)
    Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by...
    TRDA competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Century Therapeutics Inc (IPSC)
    Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy...
    IPSC competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors

    Frequently Asked Questions About QTTB

    Who are Q32 Bio's main competitors?

    The companies most similar to Q32 Bio include SAB Biotherapeutics (SABS), ProQR Therapeutics BV (PRQR), Tevogen Bio Holdings (TVGN), Palisade Bio (PALI) and Nautilus Biotechnology (NAUT), listed from the closest match.

    Who is Q32 Bio's biggest competitor?

    Avalo Therapeutics (AVTX) is the largest of the similar companies at $448.71M; SAB Biotherapeutics (SABS) is the closest match by business profile, size, sector and industry.

    How does QTTB stock compare with its competitors?

    QTTB's P/E is 2.5x against a peer median of 12.1x; its P/S is 5.2x against a peer median of 6.1x; its net margin is 60.0% against a peer median of 0.0%.

    Which of Q32 Bio's competitors pays a higher dividend?

    Q32 Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Q32 Bio bigger than its competitors?

    No. Q32 Bio is 8th by market cap among the 13 companies on this page; the largest is Avalo Therapeutics (AVTX) at $448.71M.